Cover Image

Guidance for industry : Q1B photostability testing of new drug substances and products.

Bibliographic Details
Corporate Authors:	Center for Drug Evaluation and Research (U.S.), Center for Biologics Evaluation and Research (U.S.), International Conference on Harmonisation
Format:	Government Document Conference Proceeding eBook
Language:	English
Published:	Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research : Center for Biologics Evaluation and Research, [1996]
Subjects:	Drug stability. Drugs > Testing > Government policy > United States.
Online Access:	https://purl.fdlp.gov/GPO/LPS117626

Similar Items

Guidance for industry : stability testing, photostability testing of new veterinary drug substances and medicinal products.
Published: (1999)

Guidance for industry : Q1A(R2) stability testing of new drug substances and products.
Published: (2003)

Guidance for industry : Q1D bracketing and matrixing designs for stability testing of new drug substances and products.
Published: (2003)

Guidance for industry : Q1E evaluation of stability data.
Published: (2004)

Guidance for industry : expiration dating and stability testing of solid oral dosage form drugs containing iron.
Published: (1997)

Guidance for industry : stability testing of new veterinary dosage forms.
Published: (1999)

Guidance for industry : stability testing of new biotechnological/biological veterinary medicinal products.
Published: (2001)

Guidance for industry : Q1C stability testing for new dosage forms.
Published: (1996)

Guidance for industry : stability testing of new veterinary drug substances and medicinal products (revision).
Published: (2007)

Guidance for industry : ANDAs, pharmaceutical solid polymorphism, chemistry, manufacturing and controls information.
Published: (2007)

Guidance for industry : Q3A impurities in new drug substances.
Published: (2008)

Guidance for industry : stability testing for medicated premixes.
Published: (2000)

Guidance for industry : Q3B(R2) impurities in new drug products.
Published: (2006)

Guidance for industry : content and format of investigational new drug applications (INDs) for phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products.
Published: (1995)

Guidance for industry : handling and retention of BA and BE testing samples.
Published: (2004)

Guidance for industry : content and format of investigational new drug applications (INDs) for phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products.
Published: (1995)

Guidance for industry : ANDAs, impurities in drug substances.
Published: (2009)

Guidance for industry : E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, questions and answers.
Published: (2008)

Guidance for industry : drug-induced liver injury, premarketing clinical evaluation.
Published: (2009)

Guidance for industry : PAC-ATLS : postapproval changes, analytical testing laboratory sites.
Published: (1998)

Drugs, photochemistry and photostability /
Published: (1998)

Guidance for industry : ANDAs, impurities in drug products.
Published: (2005)

Guidance for industry : S1B testing for carcinogenicity of pharmaceuticals.
Published: (1997)

Guidance for industry : submitting and reviewing complete responses to clinical holds.
Published: (2000)

Guidance for industry : street drug alternatives.
Published: (2000)

Guidance for industry : CGMP for phase 1 investigational drugs.
Published: (2008)

Guidance for industry : M4Q, the CTD, quality.
Published: (2001)

Guidance for industry : Q3A impurities in new drug substances.
Published: (2008)

Guidance for industry : dosage delivery devices for OTC liquid drug products.
Published: (2009)

Guidance for industry : Q8(R2) pharmaceutical development.
Published: (2009)

Guidance for industry : investigating out-of-specification test results (OOS) for pharmaceutical production.
Published: (2006)

Guidance for industry : photosafety testing.
Published: (2003)

Pharmaceutical stability testing to support global markets /
Published: (2010)

Guidance for industry : adverse reactions section of labeling for human prescription drug and biological products, content and format.
Published: (2006)

Guidance for industry : providing regulatory submissions in electronic format, prescription drug advertising and promotional labeling.
Published: (2001)

Guidance for industry : potassium chloride modified-release tablets and capsules, in vivo bioequivalence and in vitro dissolution testing.
Published: (2005)

Guidance for FDA staff and industry : marketed unapproved drugs, compliance policy guide.
Published: (2006)

Guidance for industry : Q4B evaluation and recommendation of pharmocopoeial texts for use in the ICH regions : annex 3 test for particulate contamination, subdivisible particles general chapter.
Published: (2009)

Steal this urine test : fighting drug hysteria in America /
by: Hoffman, Abbie
Published: (1987)

Guidance for industry : nonclinical safety evaluation of pediatric drug products.
Published: (2006)